The latest from Augustine Therapeutics

Augustine Therapeutics announces first patient dosed in Phase I clinical trial evaluating lead candidate AGT-100216 for the treatment of Charcot-Marie-Tooth disease

Augustine Therapeutics appoints Rie Schultz Hansen, PhD as Chief Scientific Officer and establishes Copenhagen-based subsidiary

Augustine Therapeutics builds its Management Team with Virginie Cartage joining as CFO and Dr. Andy Hu as CBO

Augustine Therapeutics appoints Industry Veteran Pascale Witz as Chair of its Board of Directors

Augustine Therapeutics raises oversubscribed EUR 78 million / USD 85 million Series A financing round

Augustine Therapeutics Announces Appointment of Carl Bjartmar as Chief Medical Officer

Augustine Therapeutics announces €17 million Series A1 financing round

Augustine Therapeutics awarded with a US ALS Association grant to advance novel selective HDAC6 inhibitors

Leuven, Belgium, 27 February 2024 – Augustine Therapeutics, a biotech company based in Leuven focused on developing innovative medicines for rare neurodegenerative disorders, received a 2023 Lawrence and Isabel Barnett Drug Development Program grant from the US ALS Association. The USD 300K grant will be used to support the preclinical development of a new therapeutic class of orally active and brain-penetrant small molecule HDAC6 inhibitor candidates for the potential treatment of amyotrophic lateral sclerosis (ALS), in collaboration with the VIB-KU Leuven Center for Brain & Disease Research.

Pharmaceutical giant Eli Lilly invests in Leuven's Augustine Therapeutics

Augustine Therapeutics is proud to be sponsoring and participating to the iPSC Modelling in Neuromuscular Disorders (iMND) conference from October 23-25 in Leuven.

Augustine Tx Sponsoring and Participating to the Annual Global CMT Research Convention on Sep 26-28 2024, Cambridge-MA